Historical developments of atrial septal defect closure devices: what we learn from the past

Nassif, Martina; Abdelghani, Mohammad; Bouma, Berto J.; Straver, Bart; Blom, Nico A.; Koch, Karel T.; Tijssen, Jan G.P.; Mulder, Barbara J.M.; Winter, Robbert J. de

doi:10.1080/17434440.2016.1182860

Cited by 39 publications

(24 citation statements)

References 77 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, this device has a unique release mechanism resembling that of a bioptome with flexible angulation (from a range of 45° to full circular motion between the device and delivery cable). Because of these convenient features and its exceptional design, the device has softer braiding than the original Amplatzer ® device; therefore, it can conform to the defect anatomy and reduce the risk of erosion 4)…”

Section: Discussionmentioning

confidence: 99%

“…The optimal device should be readily positionable, facilitate complete closure with minimal risk of embolization, and use a delivery technique with safe retrieving and redeploying qualities 4). Additionally, it must be patient-friendly, facilitate rapid re-endothelialization, and be biocompatible and suitable for treating a wide range of defect characteristics.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early to Mid-Term Follow-Up Outcomes of Percutaneous Closure of Atrial Septal Defects Using Recent Generation Devices: a Single-Center Experience

et al. 2019

View full text Add to dashboard Cite

Background and Objectives: This study aimed to describe our early to mid-term experience with transcatheter atrial septal defect (ASD) closure using the Occlutech Figulla ® Flex II device (FSO), Gore ® Cardioform septal occluder (GSO), and Amplatzer ® septal occluder (ASO) after they were first approved in Korea in 2014, and to compare the three aforementioned kinds of ASD closure devices. Methods: Between September 2014 and August 2016, 267 patients underwent transcatheter ASD closure in our institution. Baseline characteristics, hemodynamic features, comorbidities, and procedural success and complication rates were analyzed retrospectively. The unpaired Student t-test or variance analysis was used in the statistical analysis. Results: The FSO was most commonly used (n=152, 56.9%), followed by the ASO (n=98, 36.7%) and GSO (n=17, 6.4%). Baseline characteristics and hemodynamic features were similar between the devices, except that the defect size and pulmonary flow-to-systemic flow ratio were lower in the GSO group than in the other groups. Overall, the procedural success rate remained at 100%, and major complication rate was <1%. No late complication occurred during the follow-up. Conclusions: The FSO and GSO are feasible, safe options for use in transcatheter ASD closure, and they are comparable to the ASO.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Early to Mid-Term Follow-Up Outcomes of Percutaneous Closure of Atrial Septal Defects Using Recent Generation Devices: a Single-Center Experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Carag Bioresorbable Septal Occluder (CBRO) (CARAG AG, Baar, Switzerland) is a self-centering, double disk device without any metal framework, composed of poly lactic-co-glycolic acid (59). Endothelialization of the device seems to be completed within 3 months, while the device usually starts to be resorbed after 6 months and completely resolved within 2 years.…”

Section: Carag Bioresorbable Septal Occluder (Figure 7i)mentioning

confidence: 99%

Transcatheter closure of atrial septal defect: principles and available devices

Jung¹,

Choi²

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

There has been a remarkable improvement in the treatment strategy of secundum atrial septal defect (ASD) over the last few decades. Indebted to the improvement in device technology and procedural techniques, transcatheter closure of ASD is currently accepted as the treatment of choice in most patients with secundum ASD. Recent generation devices enable easy and safe deployment of device with the properties of adequate flexibility, re-capturability and repositioning. Use of biocompatible materials with improved device design and refined equipment finish may promote re-endothelialization and reduce potential damage to nearby structures. Most of currently available devices show excellent efficacy and comparable outcome with its own advantages and disadvantages. In addition to improvement of device properties and performance, there has been distinct improvement in procedural technique from numerous experiences of device closure of ASD. Nowadays there are well established principles regarding patient selection, pre-procedural evaluation, step-by-step details of procedure as well as post-procedural follow-up. However, an operator may encounter pitfalls in closing complex lesions such as large defect, rim deficiencies and multiple defects, so every operator has to be familiar with each available device, general principle as well as special issues for complex lesions.

show abstract

“…5,219 Percutaneously placed PFO closure devices are a less invasive option than open surgery. 220 Six main clinical trials have evaluated closure compared with antithrombotic therapy. Three trials (CLOSURE, PC, and RESPECT) were published from 2012 to 2013, while three more recent trials (CLOSE, REDUCE, and DEFENSE-PFO) were published from 2017 to 2018.…”

Section: Epidemiology and Pathophysiologymentioning

confidence: 99%

Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease

2021

View full text Add to dashboard Cite

Prevention of ischemic stroke relies on the use of antithrombotic medications comprising antiplatelet agents and anticoagulation. Stroke risk is particularly high in patients with cardiovascular disease. This review will focus on the role of antithrombotic therapies in the context of different types of cardiovascular disease. We will discuss oral antiplatelet medications and both IV and parental anticoagulants. Different kinds of cardiovascular disease contribute to stroke via distinct pathophysiological mechanisms, and the optimal treatment for each varies accordingly. We will explore the mechanism of stroke and evidence for antithrombotic therapy in the following conditions: atrial fibrillation, prosthetic heart values (mechanical and bioprosthetic), aortic arch atherosclerosis, congestive heart failure (CHF), endocarditis (infective and nonbacterial thrombotic endocarditis), patent foramen ovale (PFO), left ventricular assist devices (LVAD), and extracorporeal membrane oxygenation (ECMO). While robust data exist for antithrombotic use in conditions such as atrial fibrillation, optimal treatment in many situations remains under active investigation.

show abstract

Historical developments of atrial septal defect closure devices: what we learn from the past

Cited by 39 publications

References 77 publications

Early to Mid-Term Follow-Up Outcomes of Percutaneous Closure of Atrial Septal Defects Using Recent Generation Devices: a Single-Center Experience

Early to Mid-Term Follow-Up Outcomes of Percutaneous Closure of Atrial Septal Defects Using Recent Generation Devices: a Single-Center Experience

Transcatheter closure of atrial septal defect: principles and available devices

Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease

Contact Info

Product

Resources

About